Mounjaro

Eli Lilly's Mounjaro Misses Out on Dedicated Sleep Apnea Approval in Europe

10 days ago

In a significant development for the pharmaceutical industry, Eli Lilly's diabetes drug, Mounjaro, has been denied a separate label for the treatment of sleep apnea in Europe. This decision, announced recently, highlights the ongoing complexities within the regulatory landscape governing medical treatments and their approvals across different markets.

Lilly Commits $3 Billion to Expand Supply of Weight-Loss Drug

18 days ago

In a significant move aimed at addressing the soaring demand for its weight-loss medication, Eli Lilly has announced plans to allocate $3 billion towards expanding the production capacity of its breakthrough drug, tirzepatide. This decision comes as obesity rates continue to rise globally, and the pharmaceutical company seeks to meet the needs of an increasing number of patients looking for effective weight management solutions.

Pharmaceutical Game Changer: Mounjaro and Zepbound Supply Shortage Resolved

3 months ago

In a welcome breakthrough for both pharmaceutical companies and patients dependent on vital obesity and diabetes medicines, supply shortages of Mounjaro and Zepbound have finally been resolved. These medicines, which play a vital role in the management of diabetes and weight loss, were under short supply resulting from unforeseen demand and complex interruptions in supply. Recently, there has been promising news in the announcements of drug manufacturers as early signals of stabilization in the availability of these vital drugs have shown signs.

England's NHS Set to Offer Groundbreaking Obesity Drug from Eli Lilly to Select Patients

3 months ago

This has been a significant step in fighting obesity, and England's NHS is preparing to roll out a new drug made by one of the biggest Pharmaceuticals: Eli Lilly. The new invented drug gains much prominence due to its effectiveness in managing weight among such patients suffering from obesity.